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PRP4
THE EFFECT OF A LETTER-BASED
EDUCATIONAL PROGRAM FOR PRESCRIBERS
AND PHARMACISTS ON ADHERENCE TO
NATIONAL ASTHMA GUIDELINES AND
HEALTHCARE UTILIZATION
Coleman CI1, Reddy P2, Laster-Bradley NM3, Dorval S4,
White CM1
1University of Connecticut, Storrs, CT, USA; 2Abt Associates
Clinical Trials, Cambridge, MA, USA; 3ACS State Healthcare,
Atlanta, GA, USA; 4Department of Social Services, Hartford,
CT, USA
OBJECTIVE: To assess the effect of a letter-based inter-
vention program, targeted at prescribers and pharmacists,
on adherence to national guidelines and healthcare uti-
lization in the Connecticut asthma Medicaid population.
METHODS: A retrospective DUR was conducted from
April to June 2001. Patients with asthma in the Con-
necticut Medicaid Program submitting >1 claim per
month (over a 6-month period) for short-acting b2-
agonists were identiﬁed (intervention group; n = 135).
Patient speciﬁc intervention packets explaining the
problem, the patient’s medication proﬁle, an asthma edu-
cation leaﬂet, response form and return envelope were
mailed to the patients’ prescribers and pharmacists. A
control group of asthma patients, who were not HDB
users at baseline and drawn from the same Medicaid
program, were also identiﬁed (n = 510). Utilization of
long-term asthma control agents and spacers and health-
care utilization were compared between the intervention
and control patients 6 months after the mailing.
RESULTS: At baseline, the intervention group had lower
utilization of long-term control agents compared to the
control group (58% vs. 96%, respectively; p < 0.001) but
there was no difference after the intervention program
(65% vs. 71%, p = 0.169). A greater number of claims
were submitted for spacers in the intervention group com-
pared to control after the mailing (7% vs. 2%, p = 0.007).
Before the mailing, the intervention group incurred more
prescriber ofﬁce visits than the control group (mean ± SD;
0.46 ± 0.82 vs. 0.25 ± 0.66, p < 0.001) but this differ-
ence was not evident after the intervention program (0.24
± 0.63 vs. 0.18 ± 0.60, p = 0.283). CONCLUSION: This
intervention program had a modest impact on improving
the use of long-term control agents and reducing pre-
scriber ofﬁce visits.
PRP5
COMPLIANCE WITH ASTHMA CONTROLLER
MEDICATIONS:AN ANALYSIS OF GAPS IN CARE
AND OPPORTUNITIES FOR COST REDUCTION
Verbrugge RR, Sokol M, McGuigan K
Medco Health Solutions, Inc, Franklin Lakes, NJ, USA
OBJECTIVES: National treatment guidelines recommend
daily use of controller medications for people with per-
sistent asthma. Consistent use of controllers can help
reduce medical resource utilization, but compliance with
therapy is often poor. Our objective is to quantify the
compliance gap and the opportunity cost of current
asthma treatment in a large beneﬁt plan population.
METHODS: Asthma patients were participants in
medical and drug beneﬁt plans sponsored by a large
national employer. All were under age 65 and had con-
tinuous beneﬁt eligibility during the study period, June
1997 through May 1999. They were identiﬁed based on
medical claims for asthma-related services. During a 12-
month analysis period, medical claims and prescription
drug claims were used to track utilization. Medication
compliance was deﬁned by the percentage of days during
the analysis period that a patient had days-supply of 
a prescribed drug class; less than 80% was considered
noncompliant. Cost and utilization were modeled using
regression analysis, adjusting for age, sex, comorbidity,
disease severity, and plan type. RESULTS: Only 9.9% of
asthma patients were compliant with their prescribed
controller medications. Low compliance was common;
41.2% of patients had less than a 20% days-supply of
controller medications during the analysis period. For
quick-relief medications, the patient distribution was
skewed toward high utilization. High levels of compliance
with controller medications were found to decrease hos-
pitalization risk by 36% (comparing the highest levels 
of compliance). High compliance with controllers also
reduced asthma-related medical costs, more than offset-
ting the increase in drug costs. The return-on-investment
(ROI) for this guidelines-based increase in drug utiliza-
tion was 2 :1. CONCLUSIONS: Therapy for many
asthma patients is suboptimal, including under use of
controller medications and overuse of quick-relief med-
ications. Shifting patient utilization toward daily con-
troller use can reduce hospitalization risk and decrease
overall healthcare costs.
PRP6
COMPARISON OF RISK FOR HOSPITAL AND/OR
EMERGENCY DEPARTMENT VISITS FOR
MEDICAID PATIENTS WITH COPD
Rascati KL1, Stanford RH2, Borker RD2
1University of Texas, Austin,TX, USA; 2GlaxoSmithKline,
Research Triangle Park, NC, USA
OBJECTIVES: To compare the risk of hospital and/or
Emergency Department (ED) visits [events], based on
various treatment regimens in a population of Medicaid
patients with Chronic Obstructive Pulmonary Disease
(COPD). METHODS: Retrospective observational
cohort design. Texas Medicaid patients aged 40 to 65
years enrolled from 1998 to 2001 with a primary diag-
nosis of COPD were identiﬁed. Five index therapy
cohorts were assessed: 1) ipratropium / Combivent (IPR);
2) salmeterol (SAL); 3) inhaled corticosteroid (ICS); 4)
ICS + IPR; and 5) ICS + SAL. Subjects were followed until
they had a COPD-related event, or for 12-months,
whichever came ﬁrst. Cox proportional hazard analysis
compared therapy cohorts, assessing time to ﬁrst COP-
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related event, adjusting for gender, age, ethnicity, presence
of co-morbid respiratory diseases, number of other co-
morbidities, pre-index use of short-acting beta agonists
(SABAs), oral steroids and theophylline, and pre-index
events. RESULTS: A total of 4447 patients were identi-
ﬁed, 2435 (55%) on IPR, 1088 (24%) on ICS alone, 410
(9%) on ICS + IPR, 299 (7%) on SAL alone and 215 (5%)
on ICS + SAL. Compared to IPR alone, the use of ICS
alone (HR 0.82, 95% CI: 0.69, 0.96), SAL alone (HR
0.62, 95% CI: 0.46, 0.84), and ICS + SAL (HR 0.64, 95%
CI: 0.45, 0.91) were associated with a lower event risk
when controlling for the other factors. Factors that were
signiﬁcant predictors of an increase risk of an event were:
being white, having a co-morbid respiratory disease,
using pre-index SABAs, and having pre-index events.
CONCLUSION: The results of this analysis suggest 
that the use of inhaled corticosteroids and salmeterol
were associated with a signiﬁcant decrease in the risk of
COPD-related hospital/ED events compared to the use of
IPR alone in a population of Medicaid patients. This was
an observational retrospective analysis and these data
should be conﬁrmed by prospective studies.
PRP7
USE OF LONG-TERM ASTHMA CONTROLLER
MEDICATIONS BEFORE AND AFTER A
HOSPITALIZATION OR EMERGENCY
DEPARTMENT VISIT
Atherly A,Williams SG, Redd SC
Centers for Disease Control, Atlanta, GA, USA
OBJECTIVES: The purpose of this abstract is to examine
the use of long-term asthma controller medications
(LTACM) before and after asthma-related inpatient stays
and emergency department events (EDE). METHODS:
Data was drawn from the 1997 Medstat-Marketscan
claims database. Asthma-related events were deﬁned as
EDE or inpatient hospital stay with a primary or sec-
ondary diagnosis of asthma (ICD-9 code 493). LTACM
included corticosteroids, xanthines, leukotriene modiﬁers
and combination medications. RESULTS: The sample
included 464 individuals with an asthma-related EDE and
747 with an inpatient hospital stay. Of the EDE sample,
60% ﬁlled a prescription for LTACM during the calendar
year. A total of 32% had ﬁlled a prescription prior to the
EDE with an average of 85 days between the prescription
being ﬁlled and the EDE. Twenty percent ﬁlled a pre-
scription during the month subsequent to the EDE and
35% during the subsequent calendar year. Of those with
a hospital stay, 60% ﬁlled a prescription for LTACM
during the calendar year. Of those that ﬁlled a prescrip-
tion prior to the hospitalization, there was an average of
70.4 days between the ﬁlling of the prescription and the
event. Forty four percent of the hospital sample ﬁlled a
prescription afterward, with 65% doing so within 30
days. CONCLUSIONS: We ﬁnd that many of those
receiving care in inpatient ad emergency departments are
not using long-term controller medications. It is likely
that virtually all of these individuals have been prescribed
medications, but have not complied with the drug
regimen. Even after an adverse event, a slight majority
continues to not ﬁll prescriptions. One approach for





COMPARISON OF THE ECONOMIC IMPACT OF
MONTELUKAST AND INHALED
CORTICOSTEROID AGENTS ON ALLERGIC
RHINITIS-RELATED UTILIZATION IN PATIENTS
WITH ASTHMA
Etemad LR1, Meyer JW1, Gilmet GP2, Standford RH2,
Stephens CH2
1Ingenix, Eden Prairie, MN, USA; 2GlaxoSmithKline, Research
Triangle Park, NC, USA
OBJECTIVES: Montelukast has been approved for the
treatment of seasonal allergic rhinitis. The study’s objec-
tive was to compare allergic rhinitis (AR) associated
medical and pharmacy utilization in asthma patients with
comorbid AR initiating inhaled corticosteroids (ICS) or
montelukast (MO). METHODS: A retrospective, obser-
vational study using healthcare claims from 25 United
Healthcare plans was conducted. Subjects less than 65
years old and newly started on either ICS or MO between
01.01.1999 and 12.31.2000 were identiﬁed. Subjects
with at least one asthma (493.xx) and one AR (477.xx)
medical claim, 24 months of continuous enrollment, and
either an AR claim or a non-sedating antihistamine (NSA)
during the 12-month baseline were included. A logistic
propensity score model was constructed utilizing AR,
asthma and total health services utilization in the base-
line period and matched cohorts selected based on a
propensity score difference of £0.01. During the 12-
month follow-up, the total number of NSA and nasal 
corticosteroid (NCS) reﬁlls, total days supply of NSA
received, total AR pharmacy cost (not including asthma
medications) and total AR health services cost (pharmacy
+ medical) were determined. Wilcoxon rank sum was
used to test median differences in AR utilization.
RESULTS: A total of 1706 subjects were matched, (853
ICS and 853 MO). Compared to ICS subjects, MO sub-
jects received signiﬁcantly more reﬁlls for NSA (median
of 2.55 vs. 3.34, p < 0.0001), signiﬁcantly more days of
NSA therapy (median days supply of 30 vs. 60, p =
0.0001), and fewer NCS reﬁlls (median of 0.63 vs. 0.54,
p = 0.0459). Additionally, MO subjects had signiﬁcantly
higher median AR pharmacy cost ($130 vs. $107, p =
0.0028) and total AR cost ($279 vs. $214, p = 0.0180).
CONCLUSIONS: In this population, compared with ICS,
the use of MO in asthma subjects with comorbid AR was
associated with greater AR health services cost in the 
12-month follow-up period.
